Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1093377

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1093377

LAMEA Hospital-Acquired Infection Diagnostics Market Size, Share & Industry Trends Analysis Report By Product, By Infection Type, By Application, By Test Type, By End User, By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Latin America, Middle East and Africa Hospital-Acquired Infection Diagnostics Market would witness market growth of 11.5% CAGR during the forecast period (2022-2028).

To cure patients and aid in recovery, modern healthcare uses a variety of invasive technologies and procedures. Infections have been linked to medical devices like catheters and ventilators. Central line-associated bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections are examples of healthcare-associated infections (HAIs). Surgical site infections are infections that occur at the surgical site. This is because the illnesses pose a significant risk to patient safety, the CDC and other healthcare institutions strives to check and prevent them.

When a catheter-associated urinary tract infection is suspected, the old catheter must be withdrawn and a urine sample taken from the newly inserted catheter, ideally before antibiotics are started. The steps have been demonstrated to increase microbiological specimen output. All catheters comprising central lines and urine catheters should be withdrawn if it is no longer needed as part of the standby precautions. Antibiotics for seven days are usually indicated for catheter-associated UTIs. The antibiotic prescription could be stretched to 10-14 days if there is a slow response or bacteremia. Antimicrobial catheters, antibiotic prophylaxis, and antimicrobial catheters, in some settings, can help prevent CAUTI.

The UAE has a solid healthcare infrastructure as one of the most economically developed and diverse marketplaces in the Middle East region. The UAE government has prioritized the development of world-class healthcare infrastructure, and as a result, the sector has grown and expanded greatly in recent years. In addition, the UAE healthcare sector has grown to satisfy the country's changing demands as well as its desire to become a regional medical tourism destination. As the prevalence of lifestyle diseases rises, the populations, whose incomes are relatively high, continue to seek higher-quality healthcare. The government has committed to building healthcare infrastructure to accommodate the need.

They are liberalizing rules in order to attract international investment and better the healthcare standard and industry. The concerned authority wants to enhance health-care funding so that more data monitoring tools can be used for proactive COVID contact tracing and virtual medical service providers can be licensed. The government also intends to strengthen national capacities to combat future pandemics, including vaccine and pharmaceutical development, digital immunization IDs, and a new supply chain strategy. The Ministry of Health wants to grow the industry by concentrating on health information technology, such as telemedicine and digital medicine.

The Brazil market dominated the LAMEA Hospital-Acquired Infection Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $115 million by 2028. The Argentina market is experiencing a CAGR of 12.1% during (2022 - 2028). Additionally, The UAE market would exhibit a CAGR of 11.2% during (2022 - 2028).

Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.

Scope of the Study

Market Segments covered in the Report:

By Product

  • Reagents & Consumables
  • Instrument

By Infection Type

  • Urinary Tract Infections (UTI)
  • Hospital Acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Others

By Application

  • Drug-Resistance Testing
  • Disease Testing

By Test Type

  • Molecular Diagnostics
  • Immunoassay
  • Urinalysis

By End User

  • Hospital
  • Standalone Laboratories
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

  • Bayer AG (Bayer Schering Pharma AG)
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Ecolab, Inc.
  • Pfizer, Inc.
  • Steris PLC
  • Johnson & Johnson
  • Abbott Laboratories
  • Merck Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Hospital-Acquired Infection Diagnostics Market, by Product
    • 1.4.2 LAMEA Hospital-Acquired Infection Diagnostics Market, by Infection Type
    • 1.4.3 LAMEA Hospital-Acquired Infection Diagnostics Market, by Application
    • 1.4.4 LAMEA Hospital-Acquired Infection Diagnostics Market, by Test Type
    • 1.4.5 LAMEA Hospital-Acquired Infection Diagnostics Market, by End User
    • 1.4.6 LAMEA Hospital-Acquired Infection Diagnostics Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Approvals and Trials
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)

Chapter 4. LAMEA Hospital-Acquired Infection Diagnostics Market by Product

  • 4.1 LAMEA Reagents & Consumables Market by Country
  • 4.2 LAMEA Instrument Market by Country

Chapter 5. LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type

  • 5.1 LAMEA Urinary Tract Infections (UTI) Market by Country
  • 5.2 LAMEA Hospital Acquired Pneumonia Market by Country
  • 5.3 LAMEA Bloodstream Infections Market by Country
  • 5.4 LAMEA Surgical Site Infections Market by Country
  • 5.5 LAMEA Gastrointestinal Infections Market by Country
  • 5.6 LAMEA Others Market by Country

Chapter 6. LAMEA Hospital-Acquired Infection Diagnostics Market by Application

  • 6.1 LAMEA Drug-Resistance Testing Market by Country
  • 6.2 LAMEA Disease Testing Market by Country

Chapter 7. LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type

  • 7.1 LAMEA Molecular Diagnostics Market by Country
  • 7.2 LAMEA Immunoassay Market by Country
  • 7.3 LAMEA Urinalysis Market by Country

Chapter 8. LAMEA Hospital-Acquired Infection Diagnostics Market by End User

  • 8.1 LAMEA Hospital Market by Country
  • 8.2 LAMEA Standalone Laboratories Market by Country
  • 8.3 LAMEA Others Market by Country

Chapter 9. LAMEA Hospital-Acquired Infection Diagnostics Market by Country

  • 9.1 Brazil Hospital-Acquired Infection Diagnostics Market
    • 9.1.1 Brazil Hospital-Acquired Infection Diagnostics Market by Product
    • 9.1.2 Brazil Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.1.3 Brazil Hospital-Acquired Infection Diagnostics Market by Application
    • 9.1.4 Brazil Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.1.5 Brazil Hospital-Acquired Infection Diagnostics Market by End User
  • 9.2 Argentina Hospital-Acquired Infection Diagnostics Market
    • 9.2.1 Argentina Hospital-Acquired Infection Diagnostics Market by Product
    • 9.2.2 Argentina Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.2.3 Argentina Hospital-Acquired Infection Diagnostics Market by Application
    • 9.2.4 Argentina Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.2.5 Argentina Hospital-Acquired Infection Diagnostics Market by End User
  • 9.3 UAE Hospital-Acquired Infection Diagnostics Market
    • 9.3.1 UAE Hospital-Acquired Infection Diagnostics Market by Product
    • 9.3.2 UAE Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.3.3 UAE Hospital-Acquired Infection Diagnostics Market by Application
    • 9.3.4 UAE Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.3.5 UAE Hospital-Acquired Infection Diagnostics Market by End User
  • 9.4 Saudi Arabia Hospital-Acquired Infection Diagnostics Market
    • 9.4.1 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Product
    • 9.4.2 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.4.3 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Application
    • 9.4.4 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.4.5 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by End User
  • 9.5 South Africa Hospital-Acquired Infection Diagnostics Market
    • 9.5.1 South Africa Hospital-Acquired Infection Diagnostics Market by Product
    • 9.5.2 South Africa Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.5.3 South Africa Hospital-Acquired Infection Diagnostics Market by Application
    • 9.5.4 South Africa Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.5.5 South Africa Hospital-Acquired Infection Diagnostics Market by End User
  • 9.6 Nigeria Hospital-Acquired Infection Diagnostics Market
    • 9.6.1 Nigeria Hospital-Acquired Infection Diagnostics Market by Product
    • 9.6.2 Nigeria Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.6.3 Nigeria Hospital-Acquired Infection Diagnostics Market by Application
    • 9.6.4 Nigeria Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.6.5 Nigeria Hospital-Acquired Infection Diagnostics Market by End User
  • 9.7 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market
    • 9.7.1 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Product
    • 9.7.2 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type
    • 9.7.3 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Application
    • 9.7.4 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type
    • 9.7.5 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by End User

Chapter 10. Company Profiles

  • 10.1 Bayer AG (Bayer Schering Pharma AG)
    • 10.1.1 Company Overview
    • 10.1.2 Financial Analysis
    • 10.1.3 Segmental and Regional Analysis
    • 10.1.4 Research & Development Expense
    • 10.1.5 Recent Strategies and Developments
      • 10.1.5.1 Partnerships, Collaborations and Agreements
  • 10.2 Danaher Corporation
    • 10.2.1 Company Overview
    • 10.2.2 Financial Analysis
    • 10.2.3 Segmental and Regional Analysis
    • 10.2.4 Research & Development Expense
  • 10.3 Becton, Dickinson and Company
    • 10.3.1 Company Overview
    • 10.3.2 Financial Analysis
    • 10.3.3 Segmental and Regional Analysis
    • 10.3.4 Research & Development Expense
    • 10.3.1 Recent Strategies and Developments
      • 10.3.1.1 Partnerships, Collaborations and Agreements
      • 10.3.1.2 Product Launches and Product Expansions
  • 10.4 Hologic, Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Financial Analysis
    • 10.4.3 Segmental and Regional Analysis
    • 10.4.4 Research & Development Expense
    • 10.4.5 Recent Strategies and Developments
      • 10.4.5.1 Partnerships, Collaborations and Agreements
      • 10.4.5.2 Product Launches and Product Expansions
  • 10.5 Ecolab, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Analysis
    • 10.5.3 Segmental and Regional Analysis
    • 10.5.4 Research & Development Expenses
    • 10.5.5 Recent Strategies and Developments
      • 10.5.5.1 Product Launches and Product Expansions:
      • 10.5.5.2 Geographical Expansions:
  • 10.6 Pfizer, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Financial Analysis
    • 10.6.3 Regional & Segmental Analysis
    • 10.6.4 Research & Development Expense
    • 10.6.5 Recent Strategies and Developments
      • 10.6.5.1 Approvals and Trials:
      • 10.6.5.2 Acquisitions and Mergers
  • 10.7 Steris PLC
    • 10.7.1 Company Overview
    • 10.7.2 Financial Analysis
    • 10.7.3 Segmental and Regional Analysis
    • 10.7.4 Research & Development Expenses
  • 10.8 Johnson & Johnson
    • 10.8.1 Company Overview
    • 10.8.2 Financial Analysis
    • 10.8.3 Segmental &Regional Analysis
    • 10.8.4 Research & Development Expenses
  • 10.9 Abbott Laboratories
    • 10.9.1 Company Overview
    • 10.9.2 Financial Analysis
    • 10.9.3 Segmental and Regional Analysis
    • 10.9.4 Research & Development Expense
    • 10.9.5 Recent Strategies and Developments
      • 10.9.5.1 Approvals and Trials:
      • 10.9.5.2 Product Launches and Product Expansions:
  • 10.10. Merck Group
    • 10.10.1 Company Overview
    • 10.10.2 Financial Analysis
    • 10.10.3 Segmental and Regional Analysis
    • 10.10.4 Research & Development Expense
    • 10.10.5 Recent Strategies and Developments
      • 10.10.5.1 Partnerships, Collaborations and Agreements

LIST OF TABLES

  • TABLE 1 LAMEA Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 2 LAMEA Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Hospital-Acquired Infection Diagnostics Market
  • TABLE 4 Product Launches And Product Expansions- Hospital-Acquired Infection Diagnostics Market
  • TABLE 5 Acquisition and Mergers- Hospital-Acquired Infection Diagnostics Market
  • TABLE 6 Approvals and Trials - Hospital-Acquired Infection Diagnostics Market
  • TABLE 7 LAMEA Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 8 LAMEA Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 9 LAMEA Reagents & Consumables Market by Country, 2018 - 2021, USD Million
  • TABLE 10 LAMEA Reagents & Consumables Market by Country, 2022 - 2028, USD Million
  • TABLE 11 LAMEA Instrument Market by Country, 2018 - 2021, USD Million
  • TABLE 12 LAMEA Instrument Market by Country, 2022 - 2028, USD Million
  • TABLE 13 LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 14 LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 15 LAMEA Urinary Tract Infections (UTI) Market by Country, 2018 - 2021, USD Million
  • TABLE 16 LAMEA Urinary Tract Infections (UTI) Market by Country, 2022 - 2028, USD Million
  • TABLE 17 LAMEA Hospital Acquired Pneumonia Market by Country, 2018 - 2021, USD Million
  • TABLE 18 LAMEA Hospital Acquired Pneumonia Market by Country, 2022 - 2028, USD Million
  • TABLE 19 LAMEA Bloodstream Infections Market by Country, 2018 - 2021, USD Million
  • TABLE 20 LAMEA Bloodstream Infections Market by Country, 2022 - 2028, USD Million
  • TABLE 21 LAMEA Surgical Site Infections Market by Country, 2018 - 2021, USD Million
  • TABLE 22 LAMEA Surgical Site Infections Market by Country, 2022 - 2028, USD Million
  • TABLE 23 LAMEA Gastrointestinal Infections Market by Country, 2018 - 2021, USD Million
  • TABLE 24 LAMEA Gastrointestinal Infections Market by Country, 2022 - 2028, USD Million
  • TABLE 25 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 26 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 27 LAMEA Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 28 LAMEA Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 29 LAMEA Drug-Resistance Testing Market by Country, 2018 - 2021, USD Million
  • TABLE 30 LAMEA Drug-Resistance Testing Market by Country, 2022 - 2028, USD Million
  • TABLE 31 LAMEA Disease Testing Market by Country, 2018 - 2021, USD Million
  • TABLE 32 LAMEA Disease Testing Market by Country, 2022 - 2028, USD Million
  • TABLE 33 LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 34 LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 35 LAMEA Molecular Diagnostics Market by Country, 2018 - 2021, USD Million
  • TABLE 36 LAMEA Molecular Diagnostics Market by Country, 2022 - 2028, USD Million
  • TABLE 37 LAMEA Immunoassay Market by Country, 2018 - 2021, USD Million
  • TABLE 38 LAMEA Immunoassay Market by Country, 2022 - 2028, USD Million
  • TABLE 39 LAMEA Urinalysis Market by Country, 2018 - 2021, USD Million
  • TABLE 40 LAMEA Urinalysis Market by Country, 2022 - 2028, USD Million
  • TABLE 41 LAMEA Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 42 LAMEA Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 43 LAMEA Hospital Market by Country, 2018 - 2021, USD Million
  • TABLE 44 LAMEA Hospital Market by Country, 2022 - 2028, USD Million
  • TABLE 45 LAMEA Standalone Laboratories Market by Country, 2018 - 2021, USD Million
  • TABLE 46 LAMEA Standalone Laboratories Market by Country, 2022 - 2028, USD Million
  • TABLE 47 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 48 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 49 LAMEA Hospital-Acquired Infection Diagnostics Market by Country, 2018 - 2021, USD Million
  • TABLE 50 LAMEA Hospital-Acquired Infection Diagnostics Market by Country, 2022 - 2028, USD Million
  • TABLE 51 Brazil Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 52 Brazil Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 53 Brazil Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 54 Brazil Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 55 Brazil Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 56 Brazil Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 57 Brazil Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 58 Brazil Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 59 Brazil Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 60 Brazil Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 61 Brazil Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 62 Brazil Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 63 Argentina Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 64 Argentina Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 65 Argentina Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 66 Argentina Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 67 Argentina Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 68 Argentina Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 69 Argentina Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 70 Argentina Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 71 Argentina Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 72 Argentina Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 73 Argentina Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 74 Argentina Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 75 UAE Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 76 UAE Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 77 UAE Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 78 UAE Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 79 UAE Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 80 UAE Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 81 UAE Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 82 UAE Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 83 UAE Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 84 UAE Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 85 UAE Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 86 UAE Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 87 Saudi Arabia Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 88 Saudi Arabia Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 89 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 90 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 91 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 92 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 93 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 94 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 95 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 96 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 97 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 98 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 99 South Africa Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 100 South Africa Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 101 South Africa Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 102 South Africa Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 103 South Africa Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 104 South Africa Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 105 South Africa Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 106 South Africa Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 107 South Africa Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 108 South Africa Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 109 South Africa Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 110 South Africa Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 111 Nigeria Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 112 Nigeria Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 113 Nigeria Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 114 Nigeria Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 115 Nigeria Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 116 Nigeria Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 117 Nigeria Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 118 Nigeria Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 119 Nigeria Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 120 Nigeria Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 121 Nigeria Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 122 Nigeria Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 123 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market, 2018 - 2021, USD Million
  • TABLE 124 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market, 2022 - 2028, USD Million
  • TABLE 125 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Product, 2018 - 2021, USD Million
  • TABLE 126 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Product, 2022 - 2028, USD Million
  • TABLE 127 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type, 2018 - 2021, USD Million
  • TABLE 128 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type, 2022 - 2028, USD Million
  • TABLE 129 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Application, 2018 - 2021, USD Million
  • TABLE 130 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Application, 2022 - 2028, USD Million
  • TABLE 131 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type, 2018 - 2021, USD Million
  • TABLE 132 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type, 2022 - 2028, USD Million
  • TABLE 133 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by End User, 2018 - 2021, USD Million
  • TABLE 134 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by End User, 2022 - 2028, USD Million
  • TABLE 135 Key Information - Bayer AG
  • TABLE 136 Key Information - Danaher Corporation
  • TABLE 137 Key information - Becton, Dickinson and Company
  • TABLE 138 Key information - Hologic, Inc.
  • TABLE 139 Key Information - Ecolab, Inc.
  • TABLE 140 Key Information - Pfizer, Inc.
  • TABLE 141 key information - Steris PLC
  • TABLE 142 Key information - Johnson & Johnson
  • TABLE 143 Key Information - Abbott Laboratories
  • TABLE 144 key Information - Merck GrouP

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
  • FIG 4 Recent Strategies and Developments: Becton, Dickinson and Company
  • FIG 5 Recent Strategies and Developments: Hologic, Inc.
  • FIG 6 Recent Strategies and Developments: Ecolab, Inc.
  • FIG 7 Recent Strategies and Developments: Pfizer, Inc.
  • FIG 8 Recent Strategies and Developments: Abbott Laboratories
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!